About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Speaker: Dr. Pablo Mir. Movement Disorders Unit, Department of Neurology and Clinical Neurophysiology, Institute of Biomedicine of Seville, Hospital Universitario Virgen del Rocío/University of Seville/CSIC/CIBERNED, Seville, Spain- Biomedical Research Network Center on Neurodegenerative Diseases (CIBERNED), Carlos III Health Institute, Madrid, Spain - Department of Medicine, Faculty of Medicine, University of Seville, Seville, Spain.
Abstract Parkinson’s disease (PD) is one of the most common neurodegenerative disorders, with neuroinflammation playing a significant role in its etiology and progression. Both central and peripheral immune responses are involved, and evidence suggests a brain-periphery interaction in PD. Changes in leukocyte subpopulations have been observed in PD patients, making the neutrophil-to-lymphocyte ratio (NLR) a relevant marker of peripheral inflammation. Patients with PD have a higher NLR compared to healthy controls, indicating increased peripheral inflammation. This higher NLR suggests that the neutrophil-to-lymphocyte ratio is a useful non-invasive biomarker of systemic inflammation in PD. The peripheral immune response differs among patients based on their genetic background, with those having sporadic and GBA-associated PD showing a higher NLR in contrast to those with LRRK2-associated PD. Furthermore, this elevated peripheral inflammation is associated with dopaminergic neurodegeneration, underscoring the importance of understanding inflammatory processes in the context of PD for better diagnostic and therapeutic strategies.
Host: Dr. Ariadna Laguna. Main researcher Neurodegenerative Diseases (VHIR)
Register here to attend by Zoom: https://gencat.zoom.us/j/94801616000